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Abstract
Background: Relationships among dietary sugars and a variety of chronic diseases have spawned interest in
investigating the metabolic effects of dietary sugars. An approach developed by the Agency for Healthcare
Research and Quality (AHRQ) for assessing Future Research Needs (FRN) was implemented with modifications
that integrated an evidence mapping process.
Methods: A panel of 14 stakeholders across 7 pre-defined areas of expertise (lay audience, policy makers, health
providers, research funders, evidence-based methodologists, product makers, and researchers) was assembled to
prioritize research needs. The panel was facilitated by an independent research team. A total of 213 studies were
analyzed descriptively for evidence mapping, and the results were used to inform the stakeholder panel
discussions on research needs.
Results: The stakeholder panel identified and prioritized 14 sets of research questions. The top three high-priority
FRN questions selected by the stakeholder panel focused on the effects of dietary sugars on body weight or
body composition, fat deposition, and satiety and appetite. Research considerations for the top three research
questions and crosscutting research design issues are discussed.
Conclusion: Involving a multidisciplinary stakeholder panel to prioritize the direction of future research in this or
other content areas has potential to add diverse perspectives to the determination of research needs, and to the
development of public health policy.
Keywords: Future research needs projects, Sugars, Body weight, Body composition, Appetite, Satiety
Background
Systematic reviews are valuable not only to synthesize
evidence to inform policy or practice, but also to identify
the ‘evidence gaps’ or ‘research gaps’ that limit their
ability to answer the questions posed. Structured ap-
proaches for examining the results of systematic reviews
and prioritizing research gaps from systematic reviews
have recently become more common and developed [1].
The main advantages of these approaches include the
transparency of the process, results that are easily
interpretable, and the need for modest resources in
terms of funds and time required. As part of a new effort
in 2010, the Agency for Healthcare Research and Quality
(AHRQ) supported a series of Future Research Needs
(FRN) projects, in which stakeholders were engaged
after the completion of comparative effectiveness re-
views to help develop and prioritize the future research
needed by decision makers in a variety of healthcare
content areas [2]. Concurrently a series of research
papers on various methodologic issues identified
through the initial pilot FRN projects was published to
inform eventual guidance on the determination and
prioritization of future research needs for the AHRQ’s
Effective Health Care (EHC) Program [3]. In the AHRQ
EHC program, the FRN process begins by identifying a
* Correspondence: Mei_Chun.Chung@tufts.edu
1Nutrition/Infection Unit, Department of Public Health and Community
Medicine, School of Medicine, Tufts University, Medford, USA
Full list of author information is available at the end of the article
© The Author(s). 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Chung et al. BMC Nutrition  (2016) 2:66 
DOI 10.1186/s40795-016-0108-0
list of evidence gaps from a systematic review. Then the
systematic review team works with a stakeholder panel
to first elaborate and then consolidate the evidence gaps.
Potential research questions are then formalized follow-
ing the PICOTS (Population, Intervention, Comparator,
Outcome, Timing, and Study Design) framework with
the exception of methodological questions. Finally, the
research questions are prioritized by the stakeholders
according to a set of criteria on potential value of the
research [1].
The purpose of this paper is to present the methods
and results of an FRN project which utilized a modified
version of the AHRQ’s FRN framework for identifying
research priorities [1]. Specifically, in addition to the re-
search gaps identified from published systematic reviews
(which is the current AHRQ FRN process), we inte-
grated an evidence mapping of primary research studies
with input from a multidisciplinary stakeholder panel.
The panel members identified and prioritized research
needs linking dietary sugars and potentially related
health outcomes, based on their broad range of expert-
ise. To our knowledge, the present project is the first
FRN project with a goal to cover research questions
beyond those that were identified by systematic reviews
because of the need for covering research questions that
are important for public health nutrition.
Dietary sugars commonly refer to monosaccharides
and disaccharides. Monosaccharides include glucose,
galactose, and fructose. Fructose is the most common
naturally occurring monosaccharide, found in fruits and
vegetables. Common disaccharides include sucrose
(glucose plus fructose), lactose (glucose plus galactose),
and maltose (glucose plus glucose). Associations among
dietary sugars and a variety of chronic diseases such as
obesity have spawned interest in investigating the
metabolic effects of sugars in general. Several systematic
reviews have been published focusing on the effects of
fructose on cardiometabolic outcomes in controlled tri-
als [4–9]. Other systematic reviews have examined the
effects of dietary sugars on body weight [10, 11], and
non-alcoholic fatty liver disease or indices of liver health
[12], including both controlled trials and observational
studies. Due to the complex relationships between diet-
ary sugars and health outcomes there is a need to review
a large array of populations, outcomes of interest, and
types of studies to identify and prioritize the research
gaps in this research area. This paper will summarize the
FRN approach we used and the stakeholder panel’s
perspectives on the top three research needs identified
by this approach.
Methods
The initial scope of work was developed by the sponsor
of this project (International Life Sciences Institute
(ILSI)) in a request for proposals. Aside from their initial
feedback on our funded research proposal, the sponsor
was not involved in the later refinement of the scope of
work or the process of creating the evidence-mapping
database, other than providing a list of selected citations
for cross-referencing purposes. The list of selected
citations suggested by the sponsor was merged with the
citations identified by our literature search, and were
evaluated in the same way based on the study eligibility
criteria (Table 1).
Overall approach of this FRN project
An overview of the FRN approach we used is shown in
Fig. 1. The project consisted of a research team and a
Table 1 Study eligibility criteria
Inclusion Criteria Exclusion Criteria
Step 1 evidence map Sugar Exposures: Sucrose, fructose, sugar-sweetened
beverages, high fructose corn syrup, and total, refined
and other unspecified sugars.
Study Designs: Case–control and cross-sectional studies,
and in vitro studies.
Language: Non-English publications.
Study Designs: Intervention studies of any designa &
cohort studies.
Outcomes: Any clinical diagnosis, patient-centered outcome,
and well-established intermediate endpoints indicative of
disease risk
Populations: Human Outcomes: Dental caries and pain.
Populations: Animals
Step 2 evidence map Sugar Exposures and Study Designs: Same as Step 1. Sugar Exposures and Study Designs: Intravenous sugar
administration and sugar-sweetened beverages without
quantification of sugar amount.Additional Outcomes to Step 1: Satiety, “addiction,”
b and appetite
Outcomes: Cancer, athletic performance, and cognition.
Populations: Infants (age < 1 year old)
aNote that study design filters for randomized trials and prospective cohort studies were utilized in our search strategy. Therefore, non-randomized trials and
before-and-after trials were not completely captured by our literature search. bThe outcome term “addiction” was later removed based on the stakeholder panel’s
discussions to avoid misinterpretations. See results for stakeholders’ discussions on this issue
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stakeholder panel. The stakeholder panel was tasked
with overseeing and advising on the development of the
search strategy and study eligibility criteria for the
evidence mapping, as well as prioritization of FRN re-
search questions. The research team was tasked with
data screening, abstraction and analysis, and facilitating
stakeholder engagement and discussions. The roles and
responsibilities of different parties in the FRN project
are described in Appendix A of the Additional file 1.
A draft report underwent a period of public review in
August 2014. All public reviewers’ comments and
suggestions were considered in revising the report.
Evidence mapping
The process and methods for creating an evidence-map
database of published studies linking dietary sugars and
selected health outcomes are described in the Additional
file 2. There are currently no methodological standards
for evidence mapping. The steps of our evidence map-
ping included: 1) developing a comprehensive literature
search strategy; 2) establishing study eligibility criteria
and a systematic study selection process; 3) extracting
data; 4) developing groups of health outcomes with in-
put from the stakeholder panel; and 5) tabulating data
using descriptive analyses [13]. One of the most import-
ant features of the evidence mapping process is the
cataloging of a large number and variety of outcomes re-
ported in the published literature. For this project, the
research team solicited feedback from the stakeholder
panel to ensure that the results would be useful for their
discussion on research needs. Outcomes were grouped
into clinically and biologically relevant categories based
on stakeholder input and the research team’s expertise.
(Fig. 2) A summary report of the descriptive evidence-
mapping analysis was then presented to the stakeholder
panel to generate discussion about research gaps and
future research needs, which took place during a one-
day in-person meeting (see Appendix B of the
Additional file 1). All data were stored on SRDR™
(available on http://srdr.ahrq.gov/projects/136). The
goal of the stakeholder panel’s discussions was to bring
out different perspectives on the research questions
and priorities. Therefore, scientific evidence was not
required to support the statements or opinions raised
by the stakeholder panel.
Stakeholder panel
Stakeholders with various areas of expertise were
identified and assembled according to a framework for
stakeholder engagement in patient-centered outcomes
research [14]. Stakeholders were selected to provide
broad expertise and perspectives specific to the topic of
dietary sugars and health. A total of 14 stakeholders
with different backgrounds and expertise were initially
identified through existing networks of both the
sponsor and the research team (Table 2). Two members
(1 lay audience and 1 statistical expert) dropped out
due to personal reasons. The final stakeholder panel
consisted of 12 members across seven stakeholder
groups. Ten members participated as coauthors of the
full report and this publication.
Fig. 1 Overview of the FRN assessment approach
Chung et al. BMC Nutrition  (2016) 2:66 Page 3 of 11
Stakeholders engagement and research needs
prioritization
Stakeholders participated in a one-day in-person meet-
ing, chaired by the principal investigator (M.C.), to dis-
cuss, refine, and formulate research questions based on
the top eight outcome groups. Prior to the in-person
meeting, 25 preliminary research questions were drafted
based on the research recommendations made by the
authors of the published systematic reviews and the re-
search gaps identified by the evidence-mapping analyses.
Stakeholders provided input through comments and
discussions posted on a web-based discussion forum.
During the in-person meeting, the stakeholder panel dis-
cussed and revised these preliminary research questions.
After the in-person meeting, the stakeholder panel pro-



























































































Fig. 2 Analysis of outcomes reported in the studies in step-2 evidence map database by the outcome groupsa ranked as highest priority by the
stakeholder panelb. Legends: a Seven outcome groups were formed, namely ‘cardiovascular disease risks,’ ‘diabetes risks,’ ‘body weight/body composition,’
‘appetite,’ ‘liver health,’ ‘diet quality,’ and ‘mortality.’ Note top 7 categories include mortality but no studies reporting mortality outcome were identified in
our evidence-mapping database. Total outcomes included 367 outcomes in the “other” category. b Outcome groups are displayed in different colors –
Cardiovascular Disease Risks (green bubbles), Diabetes Risks (light orange bubbles), Body weight/ Body Composition (combined groups, yellow bubbles),
Diet Quality (red bubbles), Appetite (pink bubbles), and Liver Health (light blue bubbles). Numeric number in each bubble shows the number of studies
in each outcome category. Abbreviations: Liver health: ALT- alanine aminotransferase, AST- aspartate aminotransferase, GGT- Gamma-glutamyl
transpeptidase, GOT- serum glutamic-oxaloacetic Transaminase, DNL- de novo lipogenesis, IHCL-intrahepatic content of lipid, Cardiovascular disease
risk: LDL- low density lipoprotein cholesterol, HDL- high-density lipoprotein cholesterol, VLDL-very low-density lipoprotein
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refine and combine the research questions before the
final topic prioritization. A total of 14 sets of research
questions were agreed to by the stakeholder panel. The
Effective Health Care (EHC) Program Selection Criteria
[15] (with slight modifications for applications to the
field of public health nutrition) was then used to
prioritize the research questions. Each stakeholder was
asked to prioritize the research questions considering
four dimensions (importance, desirability, feasibility, and
potential impact), giving a score ranging from 1 (not
very important) to 5 (very important) for each dimen-
sion. An overall priority score was then calculated by
averaging the four dimension scores from all stake-
holders for each FRN research question.
Results
The literature search identified over 13,000 citations. Of
these, a total of 708 potentially relevant full-text articles
were screened, and 213 studies (202 intervention studies
and 11 prospective cohort studies) were included in our
final evidence-mapping database. (Fig. 3) Table 3 sum-
marizes the study design and population characteristics
of the intervention studies in the evidence map. Briefly,
the study populations were mostly adults (90%), 52%
were healthy at study entry, and 62.6% were males.
Study sample sizes ranged from 5 to 2,026 (mean 45)
with mean age of 35.4 and mean BMI of 23.8 kg/m2.
Over a third (36%) of these trials were studies with a
duration of <1 day. All 11 cohort studies [16–26] were
conducted in adults, of which eight were in healthy
populations, one in pregnant women, one in diabetics,
and one in a study population with mixed health status.
The sample sizes of these cohorts were large (mean
sample size = 35,738) with a wide range of follow-up
time (4 to 48 years).
The complete FRN prioritization results are described
in Table 4. Specific findings related to the top three re-
search questions are summarized below and in Table 5.
High priority research question 1
What is the long-term (>1 year) effect of a reduction in
the intake of sugars on body weight or body composition
in overweight or obese adults and children?
Evidence mapping
A total of 53 intervention studies in our evidence map
reported on body weight or body composition outcomes.
Of these, 13 studies were conducted in overweight or
obese populations. There were an equal number of stud-
ies examining the effects of isolated fructose or sucrose
on body weight, but fewer studies examining the effects
of sucrose or other sugars on body composition out-
comes compared to studies of isolated fructose. Only
two studies had intervention durations of longer than
three months. None lasted for more than one year. Of
the 11 cohort studies [16–26], one study in adults inves-
tigated the relationship between simple or added sugars
and change in waist circumference after five years [20].
A published systematic review and meta-analysis of
randomized controlled trials and prospective cohort
studies concluded that among free living people on ad
libitum diets, intake of dietary sugars or sugar sweetened
beverages is a determinant of body weight [10]. The
findings suggested that the change in body composition
that occurs with modifying intakes is mediated by
changes in energy intake, since iso-energetic exchange of
sugars with other carbohydrates was not associated with
weight change. Note that this systematic review and meta-
analysis was used to support the 2014 draft WHO guide-
lines on intake of sugars for adults and children [27].
Stakeholder discussions
There are several challenges in conducting research on
this topic that need greater emphasis. The stakeholder
panel agreed that in addition to body weight, body
composition should also be measured in future studies.
Currently, there are several tools available for measuring
body composition, such as Dual energy X-ray absorpti-
ometry (DEXA). DEXA is used as the gold standard
(over 99% accuracy) for measuring whole body adiposity
but requires specialized equipment and is therefore
expensive and cannot be measured in large, field trials.
Waist to hip ratio is commonly used to measure body
composition.
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The stakeholder panel discussed the possibility that
healthy people maintain body weight through physical
activity. Thus it is important to objectively measure
physical activity when designing studies to address this
research question (also see Table 6 for cross-cutting
study design considerations). Furthermore, there is a
need to examine whether there are differences in the
long-term (>1 year) effects of dietary sugars on body
weight or body composition between healthy and
overweight or obese populations. The stakeholder panel
considered the possibility that overweight or obese
adults and children might be more susceptible to the
effects of “high” sugars intake (not well defined) on body
weight compared to healthy counterparts, but there are
no studies addressing this question.
High priority research question 2
Do dietary sugars have a different impact on the location
of body fat deposition than other macronutrients?
Evidence mapping
Body fat deposition is related to body composition but
specifically refers to the patterns or locations of body fat
distribution. There were no studies investigating the
effects of dietary sugars on locations of body fat
deposition in the evidence-mapping database, and no
published systematic reviews on this topic as of May
2013.
Stakeholder discussions
The question regarding the effects of dietary sugars
versus other nutrients on fat deposition was first
brought up by the lay audience stakeholder in lay terms
(“whether consuming sugars would put more fat on my
waist than on other parts of my body?”). This question
was then translated into a research question by the
expert stakeholders in the panel. The panel agreed that
basic science in this area is limited, especially on how
sugars may selectively drive fat deposition and whether
N = 13,008
Search on Medline® for English language 
primary studies from 1946 to May 2013 
N = 708
Potentially relevant full-
text articles (step 1 
evidence map)
N = 213
Studies included after 
full-text screening
N = 268
Articles included in step 2 
evidence map
N = 213
Studies extracted and stored on SRDR™ 
(202 intervention trials and 11 cohort studies)
N = 31












Absorption and metabolism 
(n=11)




based on exclusion 
criteria*
N = 24
Articles added with 








Studies excluded during 
data extraction (reasons 
same as above)
Fig. 3 Literature Search and Selection Process for Evidence Mapping. Legends: *Exclusion reasons were not tracked at this stage. A low threshold
was used to exclude irrelevant abstracts, such as animal or in vitro studies, studies with no sugar exposures or outcomes of interest
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sugars are different in terms of their effects on fat de-
position compared to other energy containing nutrients
such as protein or fat. The stakeholder panel discussed
the fact that fructose, and possibly sugars in general,
would likely drive fat deposition under hyper-caloric
conditions based on the findings from studies of hyper-
caloric fructose feeding on de novo lipogenesis. Age,
gender, ethnicity, physical activity and exercise are also
likely to play a role in individual metabolism. A related
research gap is whether disease risks change with the lo-
cation of fat deposition (subcutaneous versus visceral) in
response to sugars intake.
High priority research question 3
What is the effect of sugars intake on satiety and hunger
mechanisms?
Does sugars intake affect leptin and ghrelin levels,
appetite, or fullness?
What are the different effects on satiety and appetite
between different types of sugars (fructose, sucrose, high
fructose corn syrup, honey, added sugar vs. intrinsic)?
Evidence mapping
Currently, the appetite control literature includes mainly
short-term experimental studies. In the evidence map, a
total of 32 intervention studies reported outcomes re-
lated to appetite, such as satiety, ghrelin, leptin, hunger,
appetite score, caloric compensation, peptide tyrosine
tyrosine (PYY), saliva flow, and taste. Of these, 31 stud-
ies were conducted in young adults (mean age of
30 years) with an average BMI of 26.0 kg/m2 (average of
mean BMI across studies) and trial durations ranging
from 1 day to 16 weeks. There were no published sys-
tematic reviews on this topic as of May 2013.
Stakeholder discussions
It appears that little is known about the relationships
among sugars, appetite, and brain responses in
humans, although this has been examined in animal
models [28, 29]. One stakeholder pointed out that the
current evidence shows that appetite is mainly driven by
brain mechanisms. Other stakeholders mentioned that
obesity and body composition are also related to appetite.
The literature from animal studies suggest that sugars
may attenuate the brain’s satiety responses and thus alter
appetite. However there is little data supporting this in
humans and more research is needed in this area.
The focus of this research question was whether people
compensate for calories from sugars by eating less of other
foods or if sugars had a particular characteristic that facili-
tated individuals to overcome the usual compensatory
mechanisms, thus resulting in people who consume sugars
eating more calories than they would otherwise. Some re-
searchers relate these mechanisms to the overstimulation of
reward systems similar to drug addiction, and feel strongly
that the form (liquid versus solid) in which sugars are pre-
sented may be important for this question. However, this
hypothesis has not been verified by the level of hunger or
by the level of biological mechanism, e.g. satiety hormones
or other satiety signal levels. There is currently only one ex-
perimental study (crossover design) in humans that com-
pared the effect of liquid versus solid forms of sugars on
weight or adiposity and appetite in seven males and eight
females [30]. No significant differences in hunger (self-re-
ported measures using a hunger questionnaire) between li-
quid and solid load periods were found in this study. A
larger study is needed to address this question.
Table 3 Summary of study design and population characteristics
of the included intervention studies (N = 202)
n (%) or mean (min – max)
Design
Randomized (Parallel) 47 (23%)
Randomized (Crossover) 95 (47%)
Non-randomized 25 (12%)
Single-arm 25 (12%)
Undefined trial 10 (5%)
Study Length
Acute (<1 day) 72 (36%)







> 120 10 (8%)
Sample Size 45 (5–2026)
Age, ya 35.4 (5–72)
% Malea 62.6%











aData missing for age: n = 13,% male: n = 17, and BMI: n = 114. The unit of
analysis is one study
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There are many methodological issues in the assessment
of satiety. Objective tools for consistently measuring sati-
ety, hunger or appetite outcomes are greatly needed. Fac-
tors such as culture, level of anxiety, and physical activity
can impact eating behavior but are technically difficult to
incorporate in studies with currently available measures of
appetite or satiety such as leptin, ghrelin, or adipokine
levels. The need for objective tools that can be obtained
on larger study samples for consistently measuring satiety,
hunger or appetite outcomes is enormous.
The stakeholder panel agreed that this research topic has
sufficient evidence from animal studies, but not from hu-
man studies. Although it is feasible to address this research
question in humans, this topic was suggested to be of lower
priority unless objective measurement tools that can be
used in large population-based studies for measuring
satiety, hunger or appetite outcomes are developed.
The stakeholder panel also discussed considerations
for future studies related to the top three high priority
research questions (Table 5), and identified crosscutting
study design considerations for future research (Table 6).
Discussion
This FRN report is intended to be used by researchers
and funders to help improve the usefulness of the body
of research evidence for decision makers [2]. This FRN
assessment ranked research questions regarding dietary
sugars that are of interest to general consumers, health
care professionals, and scientific researchers. Research
questions on body weight and appetite were ranked
higher than questions relating to disease risks in this
project. To our knowledge, this is the first FRN project
to integrate evidence mapping to support an FRN as-
sessment. Evidence mapping appears to be a useful
process to inform the stakeholder panel on the scope,
breadth, characteristics, and quantity of research on a
broad topic. A birds eye view of a broad research land-
scape can provide information on trends in known re-
search topics and emerging new areas of research. The
evidence mapping also highlights where the research gaps
exist, and may empower stakeholders who are not familiar
with the topic areas to participate in the FRN discussions.
Because this structured FRN approach is systematic and
transparent, it can be translated and used in other fields.
Several challenges were encountered in this FRN pro-
ject, highlighting the importance of engaging a diverse
stakeholder panel in the process. Since the evidence map-
ping covers a large number of topics, it was challenging to
organize the large number of outcomes. The evidence-
mapping research team alone did not have sufficient
Table 4 Research Question Prioritization Results
Average
score
Outcome Group Research Questions
4.20 Body weight or body composition What is the long-term (>1 year) effect of a reduction in the intake of sugars on body weight or
body composition in overweight/obese adults and children?
4.03 Body weight or body composition Do dietary sugars have a different impact on the location of body fat deposition than other
macronutrients?
3.95 Satiety or Appetite a. What is the effect of sugars intake on satiety and hunger mechanisms? b. Does sugars intake
affect leptin and ghrelin levels, appetite, or fullness? c. What are the different effects on satiety
and appetite between different types of sugars (fructose, sucrose, high fructose corn syrup, honey,
added sugar vs. intrinsic)?
3.83 Diet quality and body weight Does food source (i.e., food vs. beverage) modify the effect of sugars intake on total caloric intake,
body weight, and body composition?
3.69 Satiety or Appetite a. What are the mechanistic pathways in the brain linking sugar consumptions to a reward system
(“addictive behavior”) or insulin and glycemic levels? b. Does taste play a role in the process?
3.68 Diabetes risk How do differing patterns of dietary sugar consumption affect glycemia in pre-diabetic children,
adolescents and adults, and can dietary sugar contribute to the onset of type 2 diabetes?
3.68 Liver fat or liver health a. What are some factors that may modify the effects of dietary sugars on liver fat? b. Does sugar
consumption contribute to fatty liver independent of other factors? c. Does sugars intake modify
liver fat in the absence of a hyper-caloric diet?
3.67 Cardiovascular disease risks What factors modify the effects of sugars intake on cardiovascular disease outcomes?
3.65 Diabetes risk What factors modify the effects of sugars intake on the complications of diabetes?
3.55 Cardiovascular disease risks Does type, form, source, or timing of dietary sugars have different effects on cardiovascular disease
outcomes?
3.55 Diet quality How does a diet high in added sugars affect the overall diet quality as compared to a low sugars diet?
3.30 Diabetes risk What are the effects of sugars intake on the complications of diabetes (type 1 or type 2 diabetes)?
3.15 Cardiovascular disease risks What are the effects of sugars intake on intermediate markers of atherosclerosis?
2.98 Satiety or Appetite Is physical activity associated with a reduced sugars intake in adults?
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expertise to categorize the large number of biological
markers and endpoints. This challenge was resolved by
seeking stakeholders’ input. However, our stakeholders
also had different opinions in grouping and analyzing out-
comes because of their diverse backgrounds and expertise.
Final decisions were made based on a majority of the
stakeholders’ opinions. Therefore it is likely that a differ-
ent panel of stakeholders could reach different decisions.
Moreover, it was difficult to define the ideal composition
of a stakeholder panel when the topic areas of FRN dis-
cussions are broad. Efforts were made to create a diverse
stakeholder panel across seven areas of expertise but it is
inevitable that our panel did not represent all perspectives.
Due to budgetary constraints, we did not use the Delphi
method [31] to facilitate the consensus process of the
stakeholder panel nor formally evaluate this FRN process.
Significantly more resources (time and money) are needed
to accomplish this goal. Our evidence mapping imple-
mented a single screening process for eligible studies, so it
is possible that a few abstracts were mistakenly rejected
during this screening phase. In an effort to ensure all key
studies were included, all included citations were cross-
referenced with the reference list of relevant systematic
reviews and meta-analyses. Finally, including members of
the lay public in the FRN discussions was important to en-
sure that research questions were meaningful to general
consumers, but engaging a lay audience in the panel dis-
cussions was challenging. Some lay members may have
Table 5 Considerations for future studies related to the top
three high priority research questions
High Priority Research Question 1.
What is the long-term (>1 year) effect of a reduction in the intake of
sugars on body weight or body composition in overweight or obese adults
and children
Both long-term RCTs and large prospective cohorts on all population
groups are needed to address this evidence gap. It is important to note
that studies of weight loss need to isolate the effects of reduction in
sugars intake from the effects of total energy reduction. Also, the
macronutrient proportion in a diet and physical activity levels need
to be examined concurrently in future studies addressing the long-term
effect(s) of a reduction in sugars intake on body weight or body
composition.
High Priority Research Question 2.
Do dietary sugars have a different impact on body fat deposition than
other macronutrients?
Both controlled human metabolic studies and basic science studies
are needed to investigate this research question. The overall energy
balance of the study design is important because iso- and hyper-
caloric intake may have different metabolic effects. The metabolic
difference between iso- and hyper-caloric conditions is also in need
of investigation. Moreover, the energy balance of any comparison
group is an important design consideration in RCTs focused on
teasing out effects of different types or sources of sugars on body
composition while holding total energy constant. Overall study design
is important in examining whether sugars or other macronutrients
cause different patterns of fat deposition.
High Priority Research Question 3.
What is the effect of sugars intake on satiety and hunger mechanisms?
Does sugars intake affect leptin and ghrelin levels, appetite, or fullness?
What are the different effects on satiety and appetite between different
types of sugars (fructose, sucrose, high fructose corn syrup, honey, added
sugar vs. intrinsic)?
A systematic evidence review of all published human studies on
this topic is needed. Based on the evidence-mapping data, existing
studies have generated highly variable outcomes, depending on the
methodology used. An expert panel specifically on satiety and hunger
mechanisms is needed to assist in the interpretations of the evidence
base in order to identify existing methodological issues and to inform
future research designs. Controlled, experimental studies to develop
better measurement tools or to define reference biomarkers for
measuring satiety, hunger and appetite are of higher priority than
large scale population-based studies.
Table 6 Cross-cutting study design considerations
Crosscutting Issues Identified by the Stakeholder Panel
• Future research should use experimental conditions that approximate
realistic intake levels and chemical forms.
• There is a need to improve dietary assessment tools and methodology
because of ongoing concerns regarding systematic biases and random
errors in dietary surveys or dietary assessment methods. The
inadequacy of current methods that can potentially invalidate the
scientific findings has been discussed elsewhere [33–36].
• Controlled feeding studies cannot answer population questions.
• Statisticians or researchers with adequate statistical expertise should be
involved in a study to ensure that appropriate statistical methods are
used to control for confounders and to adjust for random
measurement errors in dietary intake assessments.
• The effect of fructose intake on blood lipids has been well established
[8, 37–39]; therefore there is no research need for this question. This is
more of a biological mechanism question than a public health
question.
• Diet quality could be an intermediate outcome for short- or long-term
(more than 1 year) clinical outcomes.
• Diet quality and meal patterns may modify the response to dietary
sugars and may need to be considered as a parameter for all studies.
• There are currently no biomarkers for sugars intake and appetite that
are considered “gold standards.”
• Body composition can change independent of weight and should be
measured whenever possible.
• Current tools to measure adiposity are either invasive or very costly.
• Exercise, fitness, and levels of other forms of physical activity will likely
modify many responses to dietary sugars and should be considered in
all studies.
• Physical activity must be measured objectively (e.g., accelerometry
based activity monitors) in clinical trials and observational studies.
• All domains of physical activity (e.g., occupational, household, transport,
leisure-time, exercise, etc.) must be measured on the population level.
The measurement of one or two domains (e.g., leisure-time and exercise)
is inadequate.
• Individual genetics may modulate effects of sugars, resulting in
heterogeneity of results
• There might be epigenetic and microbiome modulation of effects.
• There is a potential for the effects of sugars on the gut microbiome to
mediate biological effects of sugars.
• There is evidence for the hypothesis that circadian timing of intake
modulates biological effect.
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felt intimidated or may have been unable to follow the
FRN discussions due to lack of familiarity with scientific
language. Additional training and orientation of the roles
of a lay audience in FRN discussions may mitigate this
challenge. Although our FRN approach seems promising,
there is still a need to evaluate whether this process is re-
producible with a different group of equivalently represen-
tative stakeholders, and to formally conduct process
evaluations to identify areas for improvement.
Conclusions
Involving stakeholders of different backgrounds in the
research process, and using a multidisciplinary stake-
holder panel to help prioritize the direction of future re-
search may have the potential to add diverse
perspectives on how research needs are defined or deter-
mined, and to inform public health policy. Too often re-
searchers are removed from the people affected by their
research –general public/patients, practitioners/pro-
viders, or policy makers. Our experience is in line with
the Patient-Centered Outcome Research Institute
(PCORI), with a mission to bring together all healthcare
stakeholders – focusing on the community of patients –
to help set research priorities to ensure that the most
relevant research is funded and conducted. A methodo-
logical research study found that AHRQ’s FRN projects
demonstrated greater short-term (e.g., greater awareness
of the issues) than medium-term outcomes (e.g., the
generation of new knowledge) or long-term impact out-
comes (e.g., changes in patient practice or health out-
come) [32]. We expect our FRN project would have
similar impacts. Moreover, our open evidence-map data-
base can be used by researchers, research funders and
policy makers to identify research gaps and to evaluate
the quantity of evidence accumulated for a specific re-
search questions. Hence it has the potential to promote
dissemination and generation of new knowledge. With
continuous updating and data quality control, our open
evidence-map database would have the potential to pro-
mote knowledge translation from nutrition science to
policy.
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